共 50 条
Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice
被引:49
|作者:
Sun, Lei
[1
]
Yang, Xiaoxiao
[2
]
Li, Qi
[1
]
Zeng, Peng
[1
]
Liu, Ying
[1
]
Liu, Lipei
[1
]
Chen, Yuanli
[2
]
Yu, Miao
[1
]
Ma, Chuanrui
[1
]
Li, Xiaoju
[1
]
Li, Yan
[1
]
Zhang, Rongxin
[3
]
Zhu, Yan
[4
]
Miao, Qing Robert
[5
,6
]
Han, Jihong
[2
,7
]
Duan, Yajun
[2
,7
]
机构:
[1] Nankai Univ, Dept Biochem & Mol Biol, Coll Life Sci, Tianjin, Peoples R China
[2] Hefei Univ Technol, Coll Biomed Engn, Dept Biomed Sci, Hefei, Peoples R China
[3] Tianjin Med Univ, Dept Physiol, Tianjin, Peoples R China
[4] Tianjin Univ Tradit Chinese Med, Dept Pharmacol, Tianjin, Peoples R China
[5] Med Coll Wisconsin, Dept Surg, 8700 W Wisconsin Ave, Milwaukee, WI 53226 USA
[6] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA
[7] Nankai Univ, Dept Biochem & Mol Biol, Coll Life Sci, State Key Lab Med Chem Biol, Tianjin, Peoples R China
基金:
中国国家自然科学基金;
对外科技合作项目(国际科技项目);
关键词:
adiponectin;
adiponectin receptors;
AMP-activated protein kinases;
atherosclerosis;
peroxisome proliferator-activated receptors;
PLASMA-PROTEIN;
PPAR-GAMMA;
PCSK9;
CHOLESTEROL;
TRANSCRIPTION;
MODULATOR;
LIGANDS;
AGONIST;
STATINS;
BINDING;
D O I:
10.1161/ATVBAHA.117.309630
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objective-The reduced adiponectin levels are associated with atherosclerosis. Adiponectin exerts its functions by activating adiponectin receptor (AdipoR). Proprotein convertase subtilisin kexin type 9 (PCSK9) degrades LDLR protein (low-density lipoprotein receptor) to increase serum LDL-cholesterol levels. PCSK9 expression can be regulated by PPAR gamma (peroxisome proliferator-activated receptor.) or SREBP2 (sterol regulatory element-binding protein 2). The effects of AdipoR agonists on PCSK9 and LDLR expression, serum lipid profiles, and atherosclerosis remain unknown. Approach and Results-At cellular levels, AdipoR agonists (ADP355 and AdipoRon) induced PCSK9 transcription/expression that solely depended on activation of PPAR-responsive element in the PCSK9 promoter. AdipoR agonists induced PPAR gamma expression; thus, the AdipoR agonist-activated PCSK9 expression/production was impaired in PPAR gamma deficient hepatocytes. Meanwhile, AdipoR agonists transcriptionally activated LDLR expression by activating SRE in the LDLR promoter. Moreover, AMP-activated protein kinase alpha (AMPK alpha) was involved in AdipoR agonist-activated PCSK9 expression. In wild-type mice, ADP355 increased PCSK9 and LDLR expression and serum PCSK9 levels, which was associated with activation of PPAR gamma, AMPK alpha and SREBP2 and reduction of LDL-cholesterol levels. In contrast, ADP355 reduced PCSK9 expression/secretion in apoE-deficient (apoE(-/-)) mice, but it still activated hepatic LDLR, PPAR gamma, AMPK alpha, and SREBP2. More importantly, ADP355 inhibited lesions in en face aortas and sinus lesions in aortic root in apoE(-/-) mice with amelioration of lipid profiles. Conclusions-Our study demonstrates that AdipoR activation by agonists regulated PCSK9 expression differently in wildtype and apoE(-/-) mice. However, ADP355 activated hepatic LDLR expression and ameliorated lipid metabolism in both types of mice and inhibited atherosclerosis in apoE(-/-) mice. Visual Overview-An online visual overview is available for this article.
引用
收藏
页码:1290 / +
页数:22
相关论文